Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Paliperidone in the Therapy of Schizoaffective Psychosis in Adolescents (Clinical case)

E.Yu. Antokhin, V.G. Budza, O.S. Belova, S.V. Palyayeva, E.M.Kryukova
Orenburg State Medical University, Orenburg Regional Clinical Psychiatric Hospital No. 1, Orenburg, Russia

SUMMARY.
The publication describes a patient in adolescents with a first-onset psychosis with an асute onset in the form of a manic affect with irritability, delirium of other parents, depersonalization, and with delusions of persecution, expansive paraphrenia and catatonic inclusions. Treatment with paliperidone showed the possibility of a drug with a relatively rapid relief of acute psychosis. A laboratory monitoring of the prolactin level in the blood was conducted, which showed a slight increase in the average dosage of the drug, but without significant clinical manifestations of hyperprolactinaemia. There was a good tolerance of paliperidone and its high effectiveness in stopping an acute attack of psychosis in adolescence.

References: 
  • 1. Budza V.G., Antoxin E.Yu., Palaeva R.I. i dr. Sovremenny`e problemy` detskoj psixiatrii i psixofarmakologii // Psixiatriya i psixofarmakoterapiya imeni P.B. Gannushkina. – 2016. – № 5. –S. 38–41.
  • 2. Pillay J., Boylan Kh., Carrey N. et al. First- and second-generation antipsychotics in children and young adults: Systematic review update. Comparative effectiveness reviews. – No. 184. – Rockville (MD): Agency for Healthcare Research and Quality (US), 2017.
  • 3. Kupriyanova T.V., Koren` E.V. Programma (modul`) psixosocial`noj terapii dlya roditelej detej s rasstrojstvami shizofrenicheskogo spektra: ocenka kratkosrochnoj e`ffektivnosti // Sovremennaya terapiya psixicheskix rasstrojstv. – 2016. – № 4. – S. 20–26.
  • 4. Fortea A., Ilzarbe D., Espinosa L. et al. Long-acting Injectable atypical antipsychotic use in adolescents: an observational study // J Child Adolesc Psychopharmacol. – 2018. – No. 28 (4). – R. 252–257.
  • 5. Rapoport J.L. Detskaya psixofarmakologiya: slishkom mnogo ili slishkom malo? // World Psychiatry. – 2013. – № 12 (2). – S. 111–116.
  • 6. Kumar A., Datta S.S., Wright S.D.et al. Atypical antipsychotics for psychosis in adolescents // Cochrane Data base Syst. Rev. – 2013. – No. 15 (10). – CD009582.
  • 7. Instrukciya po primeneniyu lekarstvennogo preparata Invega®, soglasovannaya s Minzdravom Rossii 09.04.2013 g., registracionny`j nomer LSR-001646/07.
  • 8. Bekker R.A., By`kov Yu.V. Prolongirovanny`e antipsixotiki kompanii «Yanssen» v istoricheskom razreze: proshloe, nastoyashhee, budushhee // Psixiatriya i psixofarmakoterapiya imeni P.B. Gannushkina. – 2017. – № 6. – S. 18–27.
  • 9. Awouters F.H., Lewi P.J. Forty years of antipsychotic drug research – from haloperidol to paliperidone – with Dr. Paul Janssen // Arzneimittel for Schung. – 2007. – No. 57 (10). – S. 625–632.
  • 10. Stahl S.M., Muntner N. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. – 4th ed. – Cambridge University Press, 2013.
  • 11. Daghistani N., Rey J.A. Invega Trinza: the first four-times-a-year, long-acting injectable antipsychotic agent // P&T. – 2016. – No. 41 (4). – R.222–227.
  • 12. Retyunskij K.Yu. Osobennosti farmakokinetiki paliperidona i ego prolongirovannoj in``ekcionnoj formy` paliperidona pal`mitata // Sovremennaya terapiya psixicheskix rasstrojstv. – 2012. – № 2. – S. 25–32.
  • 13. Kozlov Ya.S., Antoxin E.Yu., Budza V.G. i dr. Paliperidona pal`mitat v terapii pervogo e`pizoda paranoidnoj shizofrenii // Sovremennaya terapiya psixicheskix rasstrojstv. – 2018. – № 2. – S. 35–40.
  • 14. Snedkov E.V. Prakticheskie rekomendacii po ispol`zovaniyu invegi (paliperidona) pri lechenii bol`ny`x shizofreniej // Obozrenie psixiatrii i medicinskoj psixologii imeni V.M. Bextereva. – 2013. – № 3. – S.112–120.
  • 15. Singh J., Robb A., Vijapurkar U. et al. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents // Biol Psychiatry. – 2011. – Vol. 70. – P. 1179–1187.
  • 16. Syunyakov T.S. Vzaimodejstviya lekarstvenny`x sredstv pri antipsixoticheskoj terapii shizofrenii: pravil`ny`e i riskovanny`e sochetaniya lekarstvenny`x sredstv // Sovremennaya terapiya psixicheskix rasstrojstv. – 2013. – № 1. – S. 11–14.
  • 17. Savitz A.J., Lane R., Nuamah I. et al. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study // J Am Acad ChildAdolesc Psychiatry. – 2015. – № 54 (2). – R. 126–137.
  • 18. Mosolov S.N., Czukarzi E`.E`., Potapov A.V. Sravnitel`naya e`ffektivnost`, perenosimost` i vliyanie na social`noe funkcionirovanie prolonga risperidona (konsta) i olanzapina pri dlitel`nom lechenii shizofrenii i shizoaffektivnogo rasstrojstva (randomizirovannoe kontroliruemoe issledovanie) // Sovremennaya terapiya psixicheskix rasstrojstv. – 2008. – № 2. – S. 10–18.
  • 19. Alfimov P.V., Ry`vkin P.V., Lady`zhenskij M.Ya., Mosolov S.N. Metabolicheskij sindrom u bol`ny`x shizofreniej (obzor literatury`) // Sovremennaya terapiya psixicheskix rasstrojstv. – 2014. – № 3. – S. 8–14.
  • 20. Madhusoodanan S., Parida S., Jimenez C. Hyperprolactinemia associated with psychotropics – a review // Journal of Psychopharmacology. – 2010. – № 25 (4). – R. 281–297.
  • 21. Balijepalli Ch., Druyts E., Zoratti M.Z. et al. Change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: a network meta-analysis // Schizophr Res Treatment. – 2018. – Publishedonline 2018 Apr 1. –- DOI: 10.1155/2018/1543034
  • 22. Gopal S., Lane R., Nuamah I. et al. Evaluation of potentially prolactin-related adverse events and sexual maturation in adolescents with schizophrenia treated with paliperidone extended-release (ER) for 2 years: a post hoc analysis of an open-label multicenter study // CNS Drugs. – 2017. – No. 31 (9). – R. 797–808. – DOI: 10.1007/s40263-017